We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
-2.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.7B
AUM Growth
-$733M
(-6.4%)
Cap. Flow
+$511M
Cap. Flow
% of AUM
4.78%
Top 10 Holdings %
Top 10 Hldgs %
33.24%
Holding
188
New
39
Increased
39
Reduced
24
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$452M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$186M |
| 3 |
CMMB
Chemomab Therapeutics
CMMB
|
+$128M |
| 4 |
Haemonetics
HAE
|
+$105M |
| 5 |
Disc Medicine
IRON
|
+$86.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prelude Therapeutics
PRLD
|
+$369M |
| 2 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
+$319M |
| 3 |
Pfizer
PFE
|
+$133M |
| 4 |
Biogen
BIIB
|
+$121M |
| 5 |
Centene
CNC
|
+$120M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.88% |
| 2 | Technology | 0.12% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Syndax Pharmaceuticals
SNDX
$1.68B
| – | – |
-1,170,900
| Closed | -$26M |
|
177
CALL
Sarepta Therapeutics
SRPT
$1.62B
| – | – |
-50,000
| Closed | -$8.53M |
|
178
Teva Pharmaceuticals
TEVA
$39.4B
| – | – |
-1,935,200
| Closed | -$18.7M |
|
179
Viatris
VTRS
$20.8B
| – | – |
-535,149
| Closed | -$10M |
|
180
Zymeworks
ZYME
$1.63B
| – | – |
-317,002
| Closed | -$15M |
|
|
TECX
181
Tectonic Therapeutic
TECX
$529M
| – | – |
-66,143
| Closed | -$11.1M |
|
|
ATNX
182
DELISTED
Athenex, Inc. Common Stock
ATNX
| – | – |
-184,703
| Closed | -$40.9M |
|
|
AKUS
183
DELISTED
Akouos Inc
AKUS
| – | – |
-315,000
| Closed | -$6.25M |
|
|
CHNG
184
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| – | – |
-3,093,700
| Closed | -$57.7M |
|
|
CALA
185
PUT
DELISTED
Calithera Biosciences, Inc
CALA
| – | – |
-12,515
| Closed | -$1.23M |
|
|
PRVL
186
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| – | – |
-13,822,463
| Closed | -$319M |
|
|
BMY.RT
187
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| – | – |
-400,000
| Closed | -$276K |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q1 2021 Portfolio in Review
As of Q1 2021, OrbiMed held 188 positions worth $10.7B, down 6.4% from $11.4B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
OrbiMed deployed $511M of net new capital in Q1 2021, opening 39 new positions and adding to 39 existing holdings. Its largest new stake was Edgewise Therapeutics: 13,944,680 shares worth $453M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Prelude Therapeutics, an estimated $369M trimmed.
- OrbiMed's largest Q1 2021 buy was Edgewise Therapeutics: 13,944,680 shares worth $453M.
- OrbiMed added most to Merck in Q1 2021, an estimated $83M increase.
- OrbiMed's biggest Q1 2021 reduction was Prelude Therapeutics, cutting an estimated $369M.
- OrbiMed fully exited Prevail Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $319M.
- OrbiMed's ten largest holdings make up 33% of its $10.7B portfolio in Q1 2021.
- OrbiMed opened 39 new positions and closed 30 in Q1 2021.
- OrbiMed's portfolio value fell 6.4% quarter-over-quarter to $10.7B.
Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.